[go: up one dir, main page]

BRPI1012859A2 - composto, composição, uso de um compostos, e, método para tratar um mamífero - Google Patents

composto, composição, uso de um compostos, e, método para tratar um mamífero

Info

Publication number
BRPI1012859A2
BRPI1012859A2 BRPI1012859A BRPI1012859A BRPI1012859A2 BR PI1012859 A2 BRPI1012859 A2 BR PI1012859A2 BR PI1012859 A BRPI1012859 A BR PI1012859A BR PI1012859 A BRPI1012859 A BR PI1012859A BR PI1012859 A2 BRPI1012859 A2 BR PI1012859A2
Authority
BR
Brazil
Prior art keywords
compound
mammal
treating
composition
Prior art date
Application number
BRPI1012859A
Other languages
English (en)
Inventor
Jacob Westman
Johan Malm
Patrizia Caldirola
Rune Ringom
Original Assignee
Clanotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clanotech Ab filed Critical Clanotech Ab
Publication of BRPI1012859A2 publication Critical patent/BRPI1012859A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI1012859A 2009-05-20 2010-05-20 composto, composição, uso de um compostos, e, método para tratar um mamífero BRPI1012859A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09160829 2009-05-20
PCT/EP2010/056968 WO2010133669A1 (en) 2009-05-20 2010-05-20 Substituted quinolines for use as vegf inhibitors

Publications (1)

Publication Number Publication Date
BRPI1012859A2 true BRPI1012859A2 (pt) 2016-04-05

Family

ID=41152142

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012859A BRPI1012859A2 (pt) 2009-05-20 2010-05-20 composto, composição, uso de um compostos, e, método para tratar um mamífero

Country Status (13)

Country Link
US (1) US20120065199A1 (pt)
EP (1) EP2432764A1 (pt)
JP (1) JP2012527431A (pt)
KR (1) KR20120023807A (pt)
CN (1) CN102625798A (pt)
AU (1) AU2010251134A1 (pt)
BR (1) BRPI1012859A2 (pt)
CA (1) CA2762232A1 (pt)
EA (1) EA201101658A1 (pt)
IL (1) IL216408A0 (pt)
MX (1) MX2011012340A (pt)
SG (1) SG176167A1 (pt)
WO (1) WO2010133669A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013103317A1 (en) * 2012-01-05 2013-07-11 Clanotech Ab Quinoline compounds which are anti-angiogenic integrin alpha5 betal inhibitors for use in the treatment of fibrosis or fibrosis-related diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400284D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
WO2008119771A2 (en) 2007-03-30 2008-10-09 Clanotech Ab Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors

Also Published As

Publication number Publication date
EP2432764A1 (en) 2012-03-28
US20120065199A1 (en) 2012-03-15
SG176167A1 (en) 2011-12-29
KR20120023807A (ko) 2012-03-13
JP2012527431A (ja) 2012-11-08
EA201101658A1 (ru) 2012-05-30
MX2011012340A (es) 2011-12-14
CA2762232A1 (en) 2010-11-25
WO2010133669A1 (en) 2010-11-25
AU2010251134A1 (en) 2011-12-08
IL216408A0 (en) 2012-02-29
CN102625798A (zh) 2012-08-01

Similar Documents

Publication Publication Date Title
BRPI1010937A2 (pt) composto, uso de um composto, e, método para tratar câncer
BRPI0920263A2 (pt) composto, uso do composto, composição, e, método
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BRPI1012978A2 (pt) composição tópica, método para preparar a mesma, e, uso de um composto
BRPI0918359A2 (pt) composto, composição agroquímica, uso da composição agroquímica e método para preparação do composto
BRPI0906906A2 (pt) Método para preparar um composto e composto
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BR112014016047A8 (pt) composição de compósito degradável, composição, e método de uso um compósito degradável
BRPI0923384A2 (pt) composto, composição farmacêutica, e, métodos para tratar um mamífero, e para inibir quimiotaxia celular
BRPI1008383A2 (pt) composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
BRPI0908252A2 (pt) Processo para preparar um composto, e, uso de um composto
BR112012002335A2 (pt) pigmento composto e método para preparação do mesmo
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI0921399A2 (pt) composição de graxa lubrificante, processo para preparar composição lubrificante, e, uso de uma composição de graxa lubrificante
BR112012004173A2 (pt) "composto, composição, método para preparar uma composição, e, uso de um composto"
BRPI1006996A2 (pt) composição, método e uso
BR112014013614A2 (pt) composição antimicrobiana, método para desinfetar uma superfície e uso de uma composição
BRPI0918955A2 (pt) preparação sólida, e, método para estabilizar um composto, e para melhorar a dissoulução de um composto
BRPI0920862A2 (pt) composição, método para fabricação da mesma, e uso da mesma
BR112012001030A2 (pt) método para tratar a degeneração macular, e, uso de um composto.
BRPI1013927A2 (pt) métodos e composições para o tratamento de lúpus
BR112013028894A2 (pt) composto de tiazol, métodos para preparação e uso do mesmo
BRPI1012047A2 (pt) compostos dímeros contendo oxazolidinona, composições e métodos para fazer e uso
BR112014013601A2 (pt) composição antimicrobiana sólida, método para desinfetar uma superfície e uso de uma composição
BRPI0811238A2 (pt) Composto, uso de um composto, composição farmacêutica, e, método para tratar um distúrbio

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.